RIPK3 and cancer: Additionally, under the effects of SMAC mimics (including SM164) and pan-caspase inhibitors (including Z-VAD-FMK), RIPK3 can interact with RIPK1 to form necrosomes, leading to the phosphorylation of MLKL and necroptosis of cancer cells [118, 119].